- Home
- ASST vs ATXS Comparison
ASST vs ATXS Comparison
Compare ASST & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASST | ATXS |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 732.4M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASST | ATXS |
|---|---|---|
| Price | $0.86 | $12.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 81.5M | 1.5M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,512,106.00 | $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 125.01 | N/A |
| 52 Week Low | $0.78 | $3.56 |
| 52 Week High | $7.89 | $13.29 |
Technical Indicators
Market Signals| Indicator | ASST | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 62.11 |
| Support Level | $0.80 | $12.64 |
| Resistance Level | $0.94 | $13.00 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 30.52 | 62.96 |
Price Performance
Historical ComparisonAbout ASST Asset Entities Inc. Class B
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.